Reality Check on Schizophrenia
Market access for schizophrenia treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 39% of the lives under commercial formularies are covered without utilization management restrictions
- Class Trends: In September 2019, Intra-Cellular Therapies, Inc. said that the FDA has informed the company that it does not have plans to schedule an advisory committee meeting in connection with the review of its New Drug Application for lumateperone for the treatment of schizophrenia
- Key Findings: There is a shift towards more integration of Medicaid benefits into managed care contracts, as well as a slight decline in the use of carve-out financing.
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.